19474-0

Delete

FDA approves sale of Baytril soft chew formulation

The antibiotic has been used for 30 years in tablet form to treat bacteria that cause skin, urinary, respiratory, and other infections

Suggested Veterinary Products

The U.S. Food and Drug Administration has approved for sale Bayer Animal Health’s Baytril Soft Chewable Tablets, based on a soft-chew formulation by Piedmont Animal Health, as a new option for administering enrofloxacin to cats and dogs.

The antibiotic has been used for 30 years in tablet form to treat bacteria that cause skin, urinary, respiratory, and other infections.

Piedmont’s soft chew uses meat-free cubes made without water, heat, or an extrusion process so they can be stably infused with active pharmaceutical ingredients.

Bayer also uses Piedmont’s soft chew for Advantus canine oral flea medicine and Quellin canine pain reliever and anti-inflammatory. Claro, a single-application treatment for canine otitis externa, gives Bayer four FDA-approved products in the last five years.

Piedmont said it will gain FDA approval for 10 or more products in the next five years.

“I fully expect that Piedmont’s current portfolio of proprietary drugs will significantly grow and disrupt the indication areas we are targeting,” said Roland Johnson, the company’s founder and CEO. “This (Baytril) approval is yet another stepping stone toward that objective.”

 

Leave a Comment

Comments

Your email address will not be published. Required fields are marked *

Register

Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).
 

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.